home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

267.41 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

How Is The Market Feeling About Krystal Biotech? ↗

July 03, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years ↗

June 25, 2024

Via Benzinga

Krystal Biotech Stock Sees RS Rating Jump To 91 ↗

June 11, 2024

On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.

Via Investor's Business Daily

ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday ↗

June 10, 2024

Via Benzinga

CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump ↗

June 07, 2024

KKR and GoDaddy also will join before the open on June 24.

Via Investor's Business Daily

Topics Stocks

How Is The Market Feeling About Krystal Biotech? ↗

May 24, 2024

Via Benzinga

(KRYS) - Analyzing Krystal Biotech's Short Interest ↗

March 13, 2024

Via Benzinga

KRYS Stock Earnings: Krystal Biotech Beats EPS, Misses Revenue for Q1 2024 ↗

May 06, 2024

KRYS stock results show that Krystal Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List ↗

March 27, 2024

Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.

Via InvestorPlace

$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today ↗

March 12, 2024

Via Benzinga

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday ↗

March 05, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

Via Benzinga

Topics Stocks

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years ↗

March 01, 2024

It will take a lot, but this goal isn't out of reach for these stocks.

Via The Motley Fool

$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today ↗

February 29, 2024

Via Benzinga

Krystal Biotech Inc. (NASDAQ: KRYS) is a Leading Gainer in 2/26 Morning Trading

February 26, 2024

Via Investor Brand Network

A Preview Of Krystal Biotech's Earnings ↗

February 23, 2024

Via Benzinga

Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results ↗

February 27, 2024

Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.

Via Benzinga

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 26, 2024

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 26, 2024

Via Benzinga

Expert Ratings for Krystal Biotech ↗

December 13, 2023

Via Benzinga

This Stock Has Quadrupled in 5 Years. Can It Do It Again? ↗

November 10, 2023

Have investors already missed the boat with this stock?

Via The Motley Fool

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

A Preview Of Krystal Biotech's Earnings ↗

November 03, 2023

Via Benzinga

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

5 Analysts Have This to Say About Krystal Biotech ↗

October 12, 2023

Via Benzinga

AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗

January 29, 2024

The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.

Via Benzinga

Topics Artificial Intelligence

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 16, 2024

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗

October 12, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023 ↗

September 07, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com